Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAAG12 is a primate-restricted N-linked carbohydrate antigen present on multiple membrane-associated proteins. It is highly expressed in colon, gastric, and pancreatic adenocarcinomas, and recognized specifically by the monoclonal antibody RAV12, which is being developed as a therapeutic agent.
RAV12 acts as an inhibitor by binding specifically to the N-linked glycotope of RAAG12 expressed on cancer cells' membranes. This interaction can block receptor function (e.g., IGF1R), disrupt signaling pathways essential for tumor growth/survival, induce oncotic cell death directly through membrane perturbation or immune effector mechanisms such as ADCC/CDC.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAAG12.